Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. (NASDAQ: LNTH) is a global leader in radiopharmaceuticals and diagnostic imaging solutions, pioneering innovations in cardiovascular, oncology, and neurology diagnostics. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s strategic developments, financial performance, and clinical advancements.
Access authoritative coverage of LNTH’s earnings reports, regulatory milestones, and product launches. Our curated collection includes press releases on new imaging agents, partnership announcements with leading medical institutions, and updates on clinical trial progress. Discover how Lantheus’ precision diagnostics and radiopharmaceutical oncology solutions continue to shape modern medical imaging.
Key updates cover FDA approvals, international expansion efforts, and technological collaborations enhancing nuclear medicine capabilities. Bookmark this page for streamlined access to essential information about LNTH’s role in advancing diagnostic accuracy and therapeutic monitoring across global healthcare systems.
Lantheus Holdings, Inc. reported a 23.0% increase in worldwide revenue to $370.0 million for the first quarter of 2024 compared to the same period in 2023. The company achieved a GAAP fully diluted net income per share of $1.87, a significant improvement from a net loss per share of $0.04 in the first quarter of 2023. Adjusted fully diluted net income per share reached $1.69, up from $1.47 in the previous year. Lantheus also enhanced its full-year 2024 net revenue and earnings guidance while providing guidance for the second quarter of 2024. The company's strong financial position and market-leading commercial portfolio set the stage for continued growth through investments in current business operations, business development, and M&A opportunities in diagnostics and therapeutics.